AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate

Seattle, Sept. 7 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax, a developer of equine vaccines to treat chronic diseases, respiratory disorders and allergies. Through this partnership, Evax advances its Antigen VLP Conjugate product into the clinical stage, and AGC Biologics will supply [...]